The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
IL-23 promotes tumour incidence and growth
Abstract
Chronic inflammation has long been associated with increased incidence of malignancy and similarities in the regulatory mechanisms have been suggested for more than a century. Infiltration of innate immune cells, elevated activities of matrix metalloproteases and increased angiogenesis and vasculature density are a few examples of the similarities between chronic and tumour-associated inflammation. Conversely, the elimination of early malignant lesions by immune surveillance, which relies on the cytotoxic activity of tumour-infiltrating T cells or intra-epithelial lymphocytes, is thought to be rate-limiting for the risk to develop cancer. Here we show a molecular connection between the rise in tumour-associated inflammation and a lack of tumour immune surveillance. Expression of the heterodimeric cytokine interleukin (IL)-23, but not of its close relative IL-12, is increased in human tumours. Expression of these cytokines antagonistically regulates local inflammatory responses in the tumour microenvironment and infiltration of intra-epithelial lymphocytes. Whereas IL-12 promotes infiltration of cytotoxic T cells, IL-23 promotes inflammatory responses such as upregulation of the matrix metalloprotease MMP9, and increases angiogenesis but reduces CD8 T-cell infiltration. Genetic deletion or antibody-mediated elimination of IL-23 leads to increased infiltration of cytotoxic T cells into the transformed tissue, rendering a protective effect against chemically induced carcinogenesis. Finally, transplanted tumours are growth-restricted in hosts depleted for IL-23 or in IL-23-receptor-deficient mice. Although many strategies for immune therapy of cancer attempt to stimulate an immune response against solid tumours, infiltration of effector cells into the tumour tissue often appears to be a critical hurdle. We show that IL-23 is an important molecular link between tumour-promoting pro-inflammatory processes and the failure of the adaptive immune surveillance to infiltrate tumours.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“IL-17 also induces proliferative signaling in keratinocytes through Act1, a major facet of its impact in psoriasis and perhaps also explaining its involvement in skin tumorigenesis”
From The IL-17 Family of Cytokines in Health and Disease (2019) · cites this paper as Langowski et al., 2006
In the citing paper
“this pro-proliferative role likely contributes to the pathogenic effects of IL-17 in psoriasis, as well as potentially in skin cancer”
From The IL-17 Family of Cytokines in Health and Disease (2019) · cites this paper as Langowski et al., 2006
In the citing paper
“In addition, as discussed above, IL-17 promotes proliferation of skin epithelial cells to promote tumorigenesis”
From The IL-17 Family of Cytokines in Health and Disease (2019) · cites this paper as Langowski et al., 2006
Citations
Cites
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
Inflammation and cancer: back to Virchow?
Balkwill, F., & Mantovani, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04046-0 · Cited by 7,746
Harrington, L. E., Hatton, R. D., Mangan, P. R., Turner, H., Murphy, T. L., Murphy, K. M., & Weaver, C. T. (2005) · Nature Immunology · doi:10.1038/ni1254 · Cited by 4,742
IL-23 drives a pathogenic T cell population that induces autoimmune inflammation
Langrish, C. L., Chen, Y., Blumenschein, W. M., Mattson, J., Basham, B., Sedgwick, J. D., McClanahan, T., Kastelein, R. A., & Cua, D. J. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041257 · Cited by 4,099
Self-citationInterleukin-12 and the regulation of innate resistance and adaptive immunity
Trinchieri, G. (2003) · Nature Reviews Immunology · doi:10.1038/nri1001 · Cited by 3,927
The Immunobiology of Cancer Immunosurveillance and Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Immunity · doi:10.1016/j.immuni.2004.07.017 · Cited by 3,032
Cua, D. J., Sherlock, J., Chen, Y., Murphy, C. A., Joyce, B., Seymour, B., Lucian, L., To, W., Kwan, S., Churakova, T., et al. (2003) · Nature · doi:10.1038/nature01355 · Cited by 2,906
Self-citationOppmann, B., Lesley, R., Blom, B., Timans, J. C., Xu, Y., Hunte, B., Vega, F., Yu, N., Wang, J., Singh, K., et al. (2000) · Immunity · doi:10.1016/s1074-7613(00)00070-4 · Cited by 2,822
Self-citationMatrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K., Tanzawa, K., Thorpe, P., Itohara, S., Werb, Z., et al. (2000) · Nature Cell Biology · doi:10.1038/35036374 · Cited by 2,797
Aggarwal, S., Ghilardi, N., Xie, M.-H., de Sauvage, F. J., & Gurney, A. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m207577200 · Cited by 1,847
MMP-9 Supplied by Bone Marrow–Derived Cells Contributes to Skin Carcinogenesis
Coussens, L. M., Tinkle, C. L., Hanahan, D., & Werb, Z. (2000) · Cell · doi:10.1016/s0092-8674(00)00139-2 · Cited by 1,306
Parham, C., Chirica, M., Timans, J., Vaisberg, E., Travis, M., Cheung, J., Pflanz, S., Zhang, R., Singh, K. P., Vega, F., et al. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.11.5699 · Cited by 1,296
Self-citationPhagocytosis of Apoptotic Neutrophils Regulates Granulopoiesis via IL-23 and IL-17
Stark, M. A., Huo, Y., Burcin, T. L., Morris, M. A., Olson, T. S., & Ley, K. (2005) · Immunity · doi:10.1016/j.immuni.2005.01.011 · Cited by 947
Lee, E., Trepicchio, W. L., Oestreicher, J. L., Pittman, D., Wang, F., Chamian, F., Dhodapkar, M., & Krueger, J. G. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20030451 · Cited by 899
Interleukin-17 promotes angiogenesis and tumor growth
Numasaki, M. (2003) · Blood · doi:10.1182/blood-2002-05-1461 · Cited by 834
IL‐12 and IL‐23: master regulators of innate and adaptive immunity
Langrish, C. L., McKenzie, B. S., Wilson, N. J., De Waal Malefyt, R., Kastelein, R. A., & Cua, D. J. (2004) · Immunological Reviews · doi:10.1111/j.0105-2896.2004.00214.x · Cited by 753
Self-citationCancer Immunotherapy: A Treatment for the Masses
Blattman, J. N., & Greenberg, P. D. (2004) · Science · doi:10.1126/science.1100369 · Cited by 612
Khader, S. A., Pearl, J. E., Sakamoto, K., Gilmartin, L., Bell, G. K., Jelley-Gibbs, D. M., Ghilardi, N., deSauvage, F., & Cooper, A. M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.2.788 · Cited by 472
Wysocka, M., Kubin, M., Vieira, L. Q., Ozmen, L., Garotta, G., Scott, P., & Trinchieri, G. (1995) · European Journal of Immunology · doi:10.1002/eji.1830250307 · Cited by 467
Tiano, H. F., Loftin, C. D., Akunda, J., Lee, C. A., Spalding, J. W., Sessoms, A. R., Dunson, D. B., Rogan, E. G., Morham, S. G., Smart, R. C., et al. (2002) · PubMed · Cited by 344
Tumors as elusive targets of T-cell-based active immunotherapy
Marincola, F. M., Wang, E., Herlyn, M., Seliger, B., & Ferrone, S. (2003) · Trends in Immunology · doi:10.1016/s1471-4906(03)00116-9 · Cited by 202
Girardi, M., Glusac, E., Filler, R. B., Roberts, S. J., Propperova, I., Lewis, J., Tigelaar, R. E., & Hayday, A. C. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021282 · Cited by 185
Antitumor and Antimetastatic Activity of IL-23
Lo, C.-H., Lee, S.-C., Wu, P.-Y., Pan, W.-Y., Su, J., Cheng, C.-W., Roffler, S. R., Chiang, B.-L., Lee, C.-N., Wu, C.-W., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.2.600 · Cited by 171
IL-23 Provides a Limited Mechanism of Resistance to Acute Toxoplasmosis in the Absence of IL-12
Lieberman, L. A., Cardillo, F., Owyang, A. M., Rennick, D. M., Cua, D. J., Kastelein, R. A., & Hunter, C. A. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.3.1887 · Cited by 169
Self-citationMueller, M. M., Herold‐Mende, C. C., Riede, D., Lange, M., Steiner, H. H., & Fusenig, N. E. (1999) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65472-7 · Cited by 129
Mini‐review: Overcoming tumor‐intrinsic resistance to immune effector function
Ganß, R., Arnold, B., & Hämmerling, G. J. (2004) · European Journal of Immunology · doi:10.1002/eji.200425474 · Cited by 75
A subset of skin tumor modifier loci determines survival time of tumor-bearing mice
Nagase, H., Mao, J., & Balmain, A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.15032 · Cited by 75
Characteristics of chemically transformed mouse epidermal cells in vitro and in vivo.
Fusenig, N. E., Amer, S. M., Boukamp, P., & Worst, P. K. M. (1978) · PubMed · Cited by 72
Modulating T-cell immunity to tumours: new strategies for monitoring T-cell responses
Yee, C., & Greenberg, P. D. (2002) · Nature reviews. Cancer · doi:10.1038/nrc820 · Cited by 70
Gupta, J. W., Kubin, M. Z., Hartman, L., Cassatella, M. A., & Trinchieri, G. (1992) · PubMed · Cited by 66
Cited by
Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008) · Nature · doi:10.1038/nature07205 · Cited by 11,399
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
“…subsets found in solid tumors are involved in tumor promotion, progression, or metastasis, including CD8+ T cells (Roberts et al., 2007), IFNγ-producing Th1 cells (Hanada et al., 2006), Th2 cells (Aspord et al., 2007; DeNardo et al., 2009) and Th17 cells (Langowski et al., 2006; Wang et al., 2009).”
InfluentialIvanov, I. I., McKenzie, B. S., Zhou, L., Tadokoro, C. E., Lepelley, A., Lafaille, J. J., Cua, D. J., & Littman, D. R. (2006) · Cell · doi:10.1016/j.cell.2006.07.035 · Cited by 5,145
STATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383
Cancer Metastasis: Building a Framework
Gupta, G. P., & Massagué, J. (2006) · Cell · doi:10.1016/j.cell.2006.11.001 · Cited by 4,247
“However, this potent response is frequently blunted during the progression of neoplasms by the tumor-derived overexpression of immunosuppressive cytokines such as TGF-β, interleukin-10, and interleukin-23 (Gorelik and Flavell, 2002; Langowski et al., 2006; Zou, 2005).”
Background
Metadata
- Authors
- Langowski, J. L., Zhang, X., Wu, L., Mattson, J. D., Chen, T., Smith, K., Basham, B., McClanahan, T., Kastelein, R. A., & Oft, M.
- Corresponding author
- Oft, Martin
- Venue
- Nature
- Published
- 2006-05-10
- Volume
- 442
- Issue
- 7101
- Pages
- 461-465
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1984467626
- Cited by
- 1,018
- References
- 30
- Citations by year
- 2026: 23 · 2025: 18 · 2024: 32 · 2023: 46 · 2022: 42 · 2021: 44 · 2020: 41 · 2019: 52 · 2018: 41 · 2017: 41 · 2016: 41 · 2015: 47 · 2014: 62 · 2013: 72 · 2012: 65
- FWCI
- 24.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- IL-23, tumour-associated inflammation, tumor surveillance, CD8+ T cell infiltration, intraepithelial lymphocytes, tumor microenvironment, angiogenesis, MMP-9, IL-12, chemical carcinogenesis, IL23R, tumor growth, cancer immunotherapy
- MeSH terms
- Animals, Cell Division, Humans, Inflammation, Interleukins, Mice, Inbred C57BL, Neoplasms, Signal Transduction, CD8-Positive T-Lymphocytes, Interleukin-12, Genetic Predisposition to Disease, Mice, Interleukin-23, Interleukin-23 Subunit p19
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.